These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 31111916)

  • 1. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide CRISPR-Cas9 knockout screens identify DNMT1 as a druggable dependency in sonic hedgehog medulloblastoma.
    Tsiami F; Lago C; Pozza N; Piccioni F; Zhao X; Lülsberg F; Root DE; Tiberi L; Kool M; Schittenhelm J; Bandopadhayay P; Segal RA; Tabatabai G; Merk DJ
    Acta Neuropathol Commun; 2024 Aug; 12(1):125. PubMed ID: 39107797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
    Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
    Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 is required for Smo-dependent signaling and mediates Smo-targeted treatment resistance and tumorigenesis in Shh medulloblastoma.
    Yuan L; Zhang H; Liu J; Malhotra A; Dey A; Yu B; Jella KK; McSwain LF; Schniederjan MJ; MacDonald TJ
    Mol Oncol; 2022 Feb; 16(4):1009-1025. PubMed ID: 34482626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHH inhibitors for the treatment of medulloblastoma.
    Samkari A; White J; Packer R
    Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
    Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
    Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.
    Zhao X; Ponomaryov T; Ornell KJ; Zhou P; Dabral SK; Pak E; Li W; Atwood SX; Whitson RJ; Chang AL; Li J; Oro AE; Chan JA; Kelleher JF; Segal RA
    Cancer Res; 2015 Sep; 75(17):3623-35. PubMed ID: 26130651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.
    Yao YL; Wang YX; Yang FC; Wang C; Mao M; Gai QJ; He J; Qin Y; Yao XX; Lan X; Zhu J; Lu HM; Zeng H; Yao XH; Bian XW; Wang Y
    CNS Neurosci Ther; 2022 Jul; 28(7):1033-1044. PubMed ID: 35419951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma.
    Lospinoso Severini L; Ghirga F; Bufalieri F; Quaglio D; Infante P; Di Marcotullio L
    Expert Opin Ther Targets; 2020 Nov; 24(11):1159-1181. PubMed ID: 32990091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.
    Brun SN; Markant SL; Esparza LA; Garcia G; Terry D; Huang JM; Pavlyukov MS; Li XN; Grant GA; Crawford JR; Levy ML; Conway EM; Smith LH; Nakano I; Berezov A; Greene MI; Wang Q; Wechsler-Reya RJ
    Oncogene; 2015 Jul; 34(29):3770-9. PubMed ID: 25241898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models.
    Daggubati V; Hochstelter J; Bommireddy A; Choudhury A; Krup AL; Kaur P; Tong P; Li A; Xu L; Reiter JF; Raleigh DR
    J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33476305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression.
    Milla LA; Arros A; Espinoza N; Remke M; Kool M; Taylor MD; Pfister SM; Wainwright BJ; Palma V
    Int J Cancer; 2014 Jan; 134(1):21-31. PubMed ID: 23775842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted treatment for sonic hedgehog-dependent medulloblastoma.
    Kieran MW
    Neuro Oncol; 2014 Aug; 16(8):1037-47. PubMed ID: 24951114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenovin-6 exhibits inhibitory effects on the growth of Sonic Hedgehog (SHH) medulloblastoma, as evidenced by both in vitro and in vivo studies.
    Wang B; Xu T; Qiu C; Yu L; Xu S; Zhao X; Xu C; Tan F; Sheng H; Zhang N
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113075. PubMed ID: 39260312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.